Vestal Point Capital’s Novavax NVAX Stock Holding History

Vestal Point Capital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-500,000	Closed	-$2.39M	–	74
2024 Q1	$2.39M	Buy	+500,000	New	+$2.32M	0.2%	51

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Vestal Point Capital's NVAX Position: Q2 2024 in Review

Vestal Point Capital sold out of Novavax (NVAX) in Q2 2024, closing a stake of 500,000 shares — an estimated $2.39M sold.

Vestal Point Capital first reported a position in NVAX in Q1 2024 and held it in 1 quarter. The position peaked at $2.39M in Q1 2024. 229 funds tracked by Wall St. Rank hold NVAX as of Q2 2024.

Vestal Point Capital reported no remaining Novavax position as of Q2 2024 after selling out during the quarter.
Vestal Point Capital sold 500,000 Novavax shares in Q2 2024, an estimated $2.39M.
Vestal Point Capital first reported a position in Novavax in Q1 2024 and held it in 1 quarter.
Vestal Point Capital's Novavax position peaked at $2.39M in Q1 2024.
229 funds tracked by Wall St. Rank held Novavax as of Q2 2024.

Based on Vestal Point Capital's 13F filing for Q2 2024, filed 14 Aug 2024.